Osteogenic Sarcoma (Osteosarcoma): Results of Therapy

Stein, Justin J.

doi:10.2214/ajr.123.3.607

Cited by 13 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports of long bone OS indicate an average age of onset in the teenage years, whereas the mean age of onset of head and neck OS is between the ages of 26 and 40 years 2–7 . Our study correlates well with a mean age at diagnosis of 37 years.…”

Section: Discussionsupporting

confidence: 83%

“…The ideal therapy regimen for OS of craniofacial bones has not yet been identified because of the small number of cases. Surgery with adequate margins remains the mainstay of treatment, 6,7,22 although the benefits of preoperative or adjuvant therapy have been controversial. Oda et al 5 suggested that while preoperative chemotherapy may not statistically improve survival, it did make the surgical resection easier.…”

Section: Discussionmentioning

confidence: 99%

“…Osteogenic sarcoma (OS) is a rare malignant bone tumor occurring in 1:100,000 people per year, 1 with about 6% to 13% of these tumors affecting the craniofacial bones 2–4 . The average age of those affected with OS of the head and neck is between 26 and 40 years, 2–7 which is 10 to 15 years older than patients with OS of the long bones. The behavior and treatment of OS have been well characterized in long bones but remain poorly understood when it affects the bones of the head and neck.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Osteosarcoma of the head and neck: A review of the johns hopkins experience

et al. 1999

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Osteosarcoma of the head and neck: A review of the johns hopkins experience

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Ten studies (10/37, 27.0%) including 559 patients (559/4594, 12.2%) reported this period [13,[31][32][33][35][36][37][38][39][40]. The average period of symptom duration was 9.9 months with a range of 0 to 36 months based on nine studies (9/10, 90.0%) including 536 patients (536/559, 95.9%) that reported a mean period [13,[31][32][33][36][37][38][39][40].…”

Section: Symptom Durationmentioning

confidence: 99%

Timing of treatment in osteosarcoma: challenges and perspectives – a scoping review

et al. 2022

View full text Add to dashboard Cite

Background The timing of events in the management of osteosarcoma may be critical for patient survivorship; however, the prognostic value of factors such as onset of symptoms or initiation of therapy in these patients has not been studied. This study sought to review the literature reporting treatment of osteosarcoma to determine the utility of event timing as a prognostic indicator. Due to significant heterogeneity in the literature, this study was conducted as a scoping review to assess the current state of the literature, identify strengths and weaknesses in current reporting practices, and to propose avenues for future improvement. Main body This review screened 312 peer-reviewed studies of osteosarcoma in any anatomic location published in an English journal for reporting of an event timing metric of any kind in a population of 6 or more. Thirty-seven studies met inclusion/exclusion criteria and were assessed for level of evidence, quality, and event timing metric. Reviewers also collated: publication year, population size, population age, tumor site, tumor type, surgical treatment, and adjuvant medical treatment. Extracted event timing data were further characterized using nine standardized categories to enable systematic analysis. The reporting of event timing in the treatment of osteosarcoma was incomplete and heterogenous. Only 37 of 312 (11.9%) screened studies reported event timing in any capacity. The period between patient-reported symptom initiation and definitive diagnosis was the most reported (17/37, 45.9%). Symptom duration was the second most reported period (10/37, 27.0%). Event timing was typically reported incidentally and was never rigorously incorporated into data analysis or discussion. No studies considered the impact of event timing on a primary outcome. The six largest studies were assessed in detail to identify pearls for future researchers. Notable shortcomings included the inadequate reporting of the definition of an event timing period and the pooling of patients into poorly defined timing groups. Conclusions Inconsistent reporting of event timing in osteosarcoma treatment prevents the development of clinically useful conclusions despite evidence to suggest event timing is a useful prognostic indicator. Consensus guidelines are necessary to improve uniformity and utility in the reporting of event timing.

show abstract

Osteosarcoma

Green¹

1985

Diagnosis and Management of Malignant Solid Tumors in Infants and Children

View full text Add to dashboard Cite

Osteogenic Sarcoma (Osteosarcoma): Results of Therapy

Cited by 13 publications

References 0 publications

Osteosarcoma of the head and neck: A review of the johns hopkins experience

Osteosarcoma of the head and neck: A review of the johns hopkins experience

Timing of treatment in osteosarcoma: challenges and perspectives – a scoping review

Osteosarcoma

Contact Info

Product

Resources

About